There are thousands of people with M.E. (Myalgic Encephalomyelitis) in Ireland. At the very best, we receive only symptom management from our doctors, that’s the best they can do for us. There is a drug, Ampligen (Rintatolimod), for the treatment of M.E.
Ampligen has been successfully trialled in the U.S.A. for the last two decades. Many M.E. patients have gone into FULL REMISSION with this drug.
This is a global petition, so can be signed no matter where you are in the world.
Please sign this petition to support a call to make Ampligen available in Ireland.
M.E. is an neurological illness as defined by the WHO (World Health Organisation). It affects all systems: neurological, immune, endocrine, gastrointestinal, musculoskeletal, etc. The symptoms can vary from mild, moderate, severe to very severe. It can be remitting/relapsing or progressive. Some people spend their days in a darkened room, unable to tolerate light or sound. Some are tube-fed. Others are mildly affected.
My name is Noreen Murphy and I live in Mullingar, Ireland. I have M.E. for over 29 years. Initially, I was very severe, then moderate for a number of years but have Severe M.E. for past few years.
[button_color url=”http://www.ipetitions.com/petition/make-the-drug-ampligen-available-for-me-patients” content=”Sign the Irish Ampligen petition” target=””]
Latest News
Submit Long COVID Drug Recommendations to RECOVER-TLC!
October 7, 2024
No Comments
Last month, RECOVER TLC met at NIH headquarters in Bethesda. The goal was to initiate a drug development strategy for Long COVID clinical trials. Now, RECOVER TLC has opened the RECOVER-TLC Intervention Information Request Form, where you can make suggestions about which drugs and other interventions to trial! Anyone can submit a therapeutic for consideration
The RECOVER-Treating Long COVID (RECOVER TLC) The Path Forward
September 26, 2024
No Comments
The RECOVER-Treating Long COVID (RECOVER TLC) Kick-off Meeting was Sept 23-25 in person and over Zoom. I had the privilege of attending over Zoom and Jaime Seltzer, #MEAction’s Scientific Director, represented the needs of the ME community in person and as an invited member of a panel on clinical trial design. There were many speakers